Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avadomide alone or with ibrutinib/obinutuzumab in CLL/SLL
NCT02406742Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2015
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of avadomide in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Celgene Corporation. Started Jul 2015; status: completed.
02
Drugs
avadomide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02406742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406742.